

# David M Holtzman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4023708/david-m-holtzman-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

456  
papers

70,834  
citations

135  
h-index

260  
g-index

529  
ext. papers

85,379  
ext. citations

11.4  
avg, IF

8.05  
L-index

#	Paper	IF	Citations
456	Murine roseolovirus does not accelerate amyloid- $\beta$ pathology and human roseoloviruses are not over-represented in Alzheimer disease brains.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 10	19	1
455	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A $\beta$ accumulation and plaque-related pathology in a mouse model of amyloidosis.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 13	19	2
454	APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.. <i>Seminars in Immunology</i> , <b>2022</b> , 101594	10.7	5
453	Astrocytic $\beta$ -Na/K ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabm4107	17.5	1
452	A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac045	4.5	2
451	In Memoriam of John T. Trojanowski, MD, PhD 1946-2022.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 24	19	0
450	ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias.. <i>Neuron</i> , <b>2022</b> ,	13.9	5
449	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer's disease.. <i>Neurobiology of Disease</i> , <b>2022</b> , 105714	7.5	0
448	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e228392	10.4	5
447	0326 Influence of Sleep and Cardiovascular Health on Cognitive Outcomes in Older Adults. <i>Sleep</i> , <b>2022</b> , 45, A147-A147	1.1	
446	Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	4
445	Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficits. <i>Neuron</i> , <b>2021</b> , 109, 741-743	13.9	3
444	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , <b>2021</b> , 7, e571	3.8	7
443	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , <b>2021</b> , 11, 239-249	2.7	5
442	Meningeal lymphatics affect microglia responses and anti-A $\beta$ immunotherapy. <i>Nature</i> , <b>2021</b> , 593, 255-260	50.4	45
441	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 396-406	17.2	41
440	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 33	51.1	114

439	A blood-based diagnostic test incorporating plasma A $\beta$ 2/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 30	19	25
438	Network dysfunction in cognitively normal APOE $\epsilon$ carriers is related to subclinical tau. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	2
437	Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. <i>Neuron</i> , <b>2021</b> , 109, 1657-1674.e7	13.9	34
436	Activated microglia mitigate A $\beta$ -associated tau seeding and spreading. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	13
435	Cognitively normal APOE $\epsilon$ carriers have specific elevation of CSF SNAP-25. <i>Neurobiology of Aging</i> , <b>2021</b> , 102, 64-72	5.6	1
434	C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. <i>Neuron</i> , <b>2021</b> , 109, 2275-2291.e8	13.9	15
433	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 49	19	7
432	Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. <i>Neuron</i> , <b>2021</b> , 109, 205-221	13.9	39
431	Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration. <i>Journal of Lipid Research</i> , <b>2021</b> , 62, 100079	6.3	1
430	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. <i>Brain</i> , <b>2021</b> ,	11.2	6
429	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. <i>Annals of Neurology</i> , <b>2021</b> , 89, 952-966	9.4	7
428	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	23
427	APOE $\epsilon$ Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All. <i>JAMA Neurology</i> , <b>2021</b> , 78, 913-915	17.2	0
426	Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. <i>Advanced Science</i> , <b>2021</b> , 8, e2101462	13.6	10
425	Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease. <i>Neuron</i> , <b>2021</b> , 109, 3199-3202	13.9	1
424	Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. <i>Neuron</i> , <b>2021</b> , 109, 2413-2426.e7	13.9	13
423	Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	18
422	Regional age-related atrophy after screening for preclinical alzheimer disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 109, 43-51	5.6	1

421	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , <b>2021</b> , 97, e18236-18345	6.1	35
420	STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks.. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 1937-3	7.3	3
419	25-Hydroxycholesterol modulates tau-mediated neurodegeneration and microglial chemotaxis and phagocytosis.. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17 Suppl 3, e056404	1.2	
418	TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. <i>Molecular Psychiatry</i> , <b>2020</b> ,	15.1	20
417	25-Hydroxycholesterol amplifies microglial IL-1 $\beta$ production in an apoE isoform-dependent manner. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 192	10.1	18
416	Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. <i>Nature Medicine</i> , <b>2020</b> , 26, 131-142	50.5	259
415	genotype regulates pathology and disease progression in synucleinopathy. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	46
414	Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 4954-4968	15.9	59
413	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. <i>SLEEP Advances</i> , <b>2020</b> , 1, zpa006	2.8	4
412	SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury. <i>Neuron</i> , <b>2020</b> , 107, 257-273.e5	13.9	18
411	Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2020</b> , 75, 1232-1241	6.4	40
410	Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression. <i>ACS Chemical Biology</i> , <b>2020</b> , 15, 3262-3274	4.9	3
409	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 513-534	14.3	63
408	Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 104-120	8.7	84
407	Functional insights from biophysical study of TREM2 interactions with apoE and A $\beta$ . <i>Alzheimer's and Dementia</i> , <b>2020</b> , 17, 475	1.2	19
406	Targeting tauopathy with engineered tau-degrading intrabodies. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 38	19	14
405	The microbiome: A target for Alzheimer disease?. <i>Cell Research</i> , <b>2019</b> , 29, 779-780	24.7	16
404	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , <b>2019</b> , 179, 312-339	56.2	721

403	The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. <i>Science</i> , <b>2019</b> , 363, 880-884	33.3	248
402	Reply to "obstructive sleep apnea treatment and amyloid- $\beta$ in cerebrospinal fluid". <i>Annals of Neurology</i> , <b>2019</b> , 85, 460-461	9.4	
401	TREM2 function impedes tau seeding in neuritic plaques. <i>Nature Neuroscience</i> , <b>2019</b> , 22, 1217-1222	25.5	92
400	Senescent glia spell trouble in Alzheimer's disease. <i>Nature Neuroscience</i> , <b>2019</b> , 22, 683-684	25.5	10
399	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 655-665	1.2	48
398	Dural lymphatics regulate clearance of extracellular tau from the CNS. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 11	19	68
397	Multi-Modal Home Sleep Monitoring in Older Adults. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	5
396	High-precision plasma $\beta$ amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , <b>2019</b> , 93, e1647-e1659	6.5	245
395	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 71	9	66
394	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1423-1434	5.3	16
393	Lack of hepatic apoE does not influence early A $\beta$ deposition: observations from a new APOE knock-in model. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 37	19	26
392	Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 2546-2561	16.6	126
391	Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 969-971	15.9	4
390	Amyloid- $\beta$ and Tau at the Crossroads of Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1184, 187-203	3.6	48
389	Dietary salt promotes cognitive impairment through tau phosphorylation. <i>Nature</i> , <b>2019</b> , 574, 686-690	50.4	68
388	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1917126	10.4	15
387	Obstructive sleep apnea treatment, slow wave activity, and amyloid- $\beta$ . <i>Annals of Neurology</i> , <b>2019</b> , 85, 291-295	9.4	42
386	Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	123

385	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , <b>2019</b> , 76, 264-273	7.2	117
384	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. <i>Nature Neuroscience</i> , <b>2019</b> , 22, 191-204	25.5	205
383	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1460-1469	1.2	120
382	ApoE facilitates the microglial response to amyloid plaque pathology. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1047-1058	16.6	115
381	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE $\epsilon$ genotype. <i>Brain</i> , <b>2018</b> , 141, 1828-1839	11.2	53
380	Dual therapy for $\beta$ -amyloidosis in AD: A successful one-two combo. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1267-1268	16.6	1
379	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 535-562	1.2	3155
378	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 241-250	24.1	224
377	Regulation of amyloid- $\beta$ dynamics and pathology by the circadian clock. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1059-1068	16.6	72
376	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , <b>2018</b> , 75, 582-590	17.2	166
375	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 168-181	15	505
374	Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 610-616	1.2	6
373	Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 869-879	1.2	80
372	Upward drift in cerebrospinal fluid amyloid $\beta$ 2 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 62-70	1.2	36
371	Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 211-223	5.6	31
370	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 205-214	1.2	70
369	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , <b>2018</b> , 34, 545-568	12.6	57
368	In Search of an Identity for Amyloid Plaques. <i>Trends in Neurosciences</i> , <b>2018</b> , 41, 483-486	13.3	8

367	Using the A/T/N Framework to Examine Driving in Preclinical AD. <i>Geriatrics (Switzerland)</i> , <b>2018</b> , 3,	2.2	4
366	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. <i>Nature Reviews Immunology</i> , <b>2018</b> , 18, 759-772	36.5	222
365	Lentiviral Vector Delivery of Orexin Gene to Study Potential Role of Orexin and Sleep Modulation in the Pathogenesis of Alzheimer's Disease <b>2018</b> , 163-175		
364	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195838	3.7	34
363	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2144-2155	15.9	72
362	Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 1213-1221	4.3	5
361	New insights into the role of TREM2 in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 66	19	161
360	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , <b>2018</b> , 141, 3233-3248	11.2	15
359	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid- $\beta$ by LRP1-dependent apolipoprotein E isoform-specific mechanism. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 57	19	94
358	High-affinity interactions and signal transduction between A $\beta$ oligomers and TREM2. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	49
357	AMPA-ergic regulation of amyloid- $\beta$ levels in an Alzheimer's disease mouse model. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 22	19	17
356	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e1295-e1306	6.5	129
355	Trisomy of human chromosome 21 enhances amyloid- $\beta$ deposition independently of an extra copy of APP. <i>Brain</i> , <b>2018</b> , 141, 2457-2474	11.2	64
354	Preclinical Alzheimer's disease and longitudinal driving decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 74-82	6	25
353	Antibody Therapeutics Targeting A $\beta$ and Tau. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2017</b> , 7,	5.4	30
352	Astrocytic LRP1 Mediates Brain A $\beta$ Clearance and Impacts Amyloid Deposition. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 4023-4031	6.6	115
351	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 839-856	14.3	107
350	Automated selective disruption of slow wave sleep. <i>Journal of Neuroscience Methods</i> , <b>2017</b> , 281, 33-39	3	2

349	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- $\beta$ and other amyloidogenic proteins. <i>Journal of Lipid Research</i> , <b>2017</b> , 58, 824-836	6.3	106
348	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 56, 25-32	5.6	36
347	AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 1227-1238	16.6	36
346	Elucidating the Role of TREM2 in Alzheimer's Disease. <i>Neuron</i> , <b>2017</b> , 94, 237-248	13.9	171
345	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	58
344	Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 58, 675-680	4.3	8
343	Altered sleep and EEG power in the P301S Tau transgenic mouse model. <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 180-190	5.3	39
342	Reply. <i>Annals of Neurology</i> , <b>2017</b> , 81, 322-323	9.4	
341	TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 11524-11529	11.5	197
340	NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia. <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 722-738	5.3	7
339	Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E9665-E9674	11.5	29
338	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. <i>Immunity</i> , <b>2017</b> , 47, 566-581.e9	32.3	988
337	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. <i>Nature</i> , <b>2017</b> , 549, 523-527	50.4	520
336	Amyloid $\beta$ concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 841-849	1.2	266
335	TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. <i>Cell</i> , <b>2017</b> , 170, 649-663.e13	56.2	441
334	Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of $\beta$ Amyloidosis. <i>Neuron</i> , <b>2017</b> , 96, 1013-1023.e4	13.9	84
333	[P2041]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/A $\beta$ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP <b>2017</b> , 13, P661-P662		
332	[F40402]: EFFECTS OF SYNAPTIC ACTIVITY ON A $\beta$ AND TAU FROM PRECLINICAL IN VIVO STUDIES: SIMILARITIES, DIFFERENCES, AND IMPLICATIONS <b>2017</b> , 13, P1215		



331	Slow wave sleep disruption increases cerebrospinal fluid amyloid- $\beta$ levels. <i>Brain</i> , <b>2017</b> , 140, 2104-2111	11.2	256
330	Glial contributions to neurodegeneration in tauopathies. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 50	19	188
329	APOE Genotype Differentially Modulates Effects of Anti-A $\beta$ Passive Immunization in APP Transgenic Mice. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 12	19	15
328	Diurnal oscillation of CSF A $\beta$ and other AD biomarkers. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 36	19	17
327	Sleep in Alzheimer's Disease - Beyond Amyloid. <i>Neurobiology of Sleep and Circadian Rhythms</i> , <b>2017</b> , 2, 4-14	2.9	87
326	[P3B91]: DRIVING CESSATION OVER A 22-YEAR PERIOD: DEMENTIA SEVERITY AND CSF BIOMARKERS <b>2017</b> , 13, P1207-P1208		1
325	[P4B85]: NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE <b>2017</b> , 13, P1335-P1335		
324	[IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK <b>2017</b> , 13, P44-P45		
323	[IC-P-064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD <b>2017</b> , 13, P53-P53		
322	[P1B02]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD <b>2017</b> , 13, P427-P428		
321	[O1B03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK <b>2017</b> , 13, P186		
320	[O1B103]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE <b>2017</b> , 13, P218-P219		
319	[O2B105]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE <b>2017</b> , 13, P550-P551		
318	[P4B63]: PREDICTION OF INCIDENT DEMENTIA: LONGITUDINAL BIOMARKER AND CLINICAL CHANGES BEFORE AND AFTER <b>2017</b> , 13, P1508-P1510		
317	[DT-01B3]: CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA <b>2017</b> , 13, P1475-P1476		
316	Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury. <i>Frontiers in Pediatrics</i> , <b>2017</b> , 5, 232	3.4	10
315	Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172353	3.7	14
314	Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein $\beta$ and L1 Cell Adhesion Molecule. <i>Neurosurgery</i> , <b>2017</b> , 80, 82-90	3.2	20

313	Longitudinal $\beta$ Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1192-1200	17.2	63
312	Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 10186-91	11.5	132
311	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2016</b> , 139, 2766-2777	11.2	48
310	Mechanisms linking circadian clocks, sleep, and neurodegeneration. <i>Science</i> , <b>2016</b> , 354, 1004-1008	33.3	325
309	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 1375-85	16.6	113
308	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> , <b>2016</b> , 80, 379-87	9.4	65
307	O2-10-05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease <b>2016</b> , 12, P252-P252		
306	The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid- $\beta$ in Young and Old APP/PS1 Mice. <i>Journal of Neuroscience</i> , <b>2016</b> , 36, 11704-11715	6.6	31
305	Tau and A $\beta$ imaging, CSF measures, and cognition in Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 338ra66	17.5	418
304	IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42, and Cognition in Alzheimer's Disease <b>2016</b> , 12, P130-P131		
303	Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 30028	4.9	314
302	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 27204-27218	5.4	27
301	Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid- $\beta$ clearance and aggregation in Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 332ra44	17.5	85
300	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , <b>2016</b> , 44, 159-172	5.6	39
299	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. <i>Brain</i> , <b>2016</b> , 139, 2249-60	11.2	125
298	Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms. <i>Methods in Pharmacology and Toxicology</i> , <b>2016</b> , 121-138	1.1	
297	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , <b>2016</b> , 79, 929-39	9.4	247
296	Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. <i>Annals of Neurology</i> , <b>2016</b> , 80, 154-9	9.4	85

295	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 292-323	1.2	832
294	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2016</b> , 73, 561-71	17.2	118
293	TREM2 Function in Alzheimer's Disease and Neurodegeneration. <i>ACS Chemical Neuroscience</i> , <b>2016</b> , 7, 420-7	5.7	80
292	Aerobic Glycolysis in the Frontal Cortex Correlates with Memory Performance in Wild-Type Mice But Not the APP/PS1 Mouse Model of Cerebral Amyloidosis. <i>Journal of Neuroscience</i> , <b>2016</b> , 36, 1871-8	6.6	45
291	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. <i>Neurobiology of Aging</i> , <b>2016</b> , 37, 208.e1-208.e9	5.6	29
290	A spectrum of exercise training reduces soluble A $\beta$ in a dose-dependent manner in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2016</b> , 85, 218-224	7.5	83
289	A single dose of the $\beta$ secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 11	9	12
288	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 925-33	14.3	201
287	Comparison of a single-channel EEG sleep study to polysomnography. <i>Journal of Sleep Research</i> , <b>2016</b> , 25, 625-635	5.8	68
286	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. <i>Scientific Reports</i> , <b>2016</b> , 6,	4.9	20
285	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 1055-64	4.3	6
284	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. <i>BMC Neurology</i> , <b>2016</b> , 16, 217	3.1	9
283	ApoE4 upregulates the activity of mitochondria-associated ER membranes. <i>EMBO Reports</i> , <b>2016</b> , 17, 27-36	6.5	88
282	CSF sTREM2: marking the tipping point between preclinical AD and dementia?. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 437-8	12	2
281	Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 74	19	108
280	P1-221: Dynamic Relationships Between Big Five Personality Traits, Alzheimer's Disease Biomarkers, and Cognition in Autosomal Dominant Alzheimer's Disease <b>2016</b> , 12, P491-P492		
279	Impaired Autophagy in APOE4 Astrocytes. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 51, 915-27	4.3	62
278	P4-150: Preclinical Alzheimer's Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons <b>2016</b> , 12, P1071-P1071		

277	P4-127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimer's Disease Clinical Trial <b>2016</b> , 12, P1062-P1062		
276	O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer's Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) <b>2016</b> , 12, P226-P226		1
275	F5-02-03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease <b>2016</b> , 12, P369-P369		
274	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network <b>2016</b> , 12, P378-P379		
273	O5-03-01: Apolipoprotein E Genotype Differentially Modulates Effects of ANTI-AB Immunotherapy <b>2016</b> , 12, P381-P382		0
272	P1-006: Emerging CSF Biomarkers of Neuroinflammation, Neuronal Injury And Synaptic Integrity in the Adni Cohort <b>2016</b> , 12, P399-P399		1
271	Tau: From research to clinical development. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 1033-1039	1.2	87
270	TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 667-75	16.6	367
269	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. <i>Neurobiology of Aging</i> , <b>2016</b> , 44, 1-8	5.6	65
268	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. <i>American Journal of Geriatric Psychiatry</i> , <b>2016</b> , 24, 1095-1104	6.5	58
267	A randomized controlled study to evaluate the effect of bexarotene on amyloid- $\beta$ and apolipoprotein E metabolism in healthy subjects. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2016</b> , 2, 110-120	6	37
266	Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 434-42	5.3	15
265	TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. <i>Cell</i> , <b>2015</b> , 160, 1061-71	56.2	847
264	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1029-42	17.2	190
263	How amyloid, sleep and memory connect. <i>Nature Neuroscience</i> , <b>2015</b> , 18, 933-4	25.5	37
262	Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 460, 439-45	3.4	10
261	Effects of CD2-associated protein deficiency on amyloid- $\beta$ in neuroblastoma cells and in an APP transgenic mouse model. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 12	19	27
260	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 656-65	17.2	66

259	Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. <i>Experimental and Molecular Medicine</i> , <b>2015</b> , 47, e148	12.8	271
258	Is there a link between the sleep-wake cycle and Alzheimer's pathology?. <i>Future Neurology</i> , <b>2015</b> , 10, 183-186	1.5	1
257	Chronic optogenetic activation augments $\alpha$ pathology in a mouse model of Alzheimer disease. <i>Cell Reports</i> , <b>2015</b> , 11, 859-865	10.6	132
256	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1771-9	5.6	30
255	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 59	9	80
254	Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology. <i>Neuron</i> , <b>2015</b> , 88, 237-9	13.9	17
253	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 339-348	5.2	23
252	Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 21652-62	5.4	75
251	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1275-80	17.2	152
250	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 11965-70	11.5	87
249	Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. <i>EBioMedicine</i> , <b>2015</b> , 2, 94-5	8.8	4
248	microRNA-33 Regulates ApoE Lipidation and Amyloid- $\beta$ Metabolism in the Brain. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 14717-26	6.6	82
247	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease <b>2015</b> , 11, P255-P255		
246	Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. <i>Acta Neuropathologica Communications</i> , <b>2015</b> , 3, 70	7.3	31
245	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease <b>2015</b> , 11, P533-P534		1
244	O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers <b>2015</b> , 11, P122-P123		
243	Anti-tau antibody reduces insoluble tau and decreases brain atrophy. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 278-88	5.3	119
242	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. <i>Neuropsychology</i> , <b>2015</b> , 29, 368-81	3.8	23

241	P2-085: Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers <b>2015</b> , 11, P516-P516		1
240	Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 469-71	6.1	40
239	Analysis of in vivo turnover of tau in a mouse model of tauopathy. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 55	19	46
238	Age and amyloid effects on human central nervous system amyloid-beta kinetics. <i>Annals of Neurology</i> , <b>2015</b> , 78, 439-53	9.4	98
237	Cerebrospinal fluid levels of amyloid precursor protein are associated with ventricular size in post-hemorrhagic hydrocephalus of prematurity. <i>PLoS ONE</i> , <b>2015</b> , 10, e0115045	3.7	22
236	Hyperglycemia modulates extracellular amyloid- $\beta$ concentrations and neuronal activity in vivo. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 2463-7	15.9	122
235	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. <i>Nature Neuroscience</i> , <b>2015</b> , 18, 800-6	25.5	435
234	IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers <b>2015</b> , 11, P24-P25		
233	F2-02-02: Effects of disrupted sleep on abeta and tau pathology and effects of abeta and tau pathology on sleep: A vicious cycle? <b>2015</b> , 11, P165-P166		1
232	F5-03-03: Academic spin-out companies <b>2015</b> , 11, P306-P306		
231	Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E881-90	11.5	96
230	Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid- $\beta$ in an APP transgenic mouse model. <i>Brain, Behavior, and Immunity</i> , <b>2015</b> , 47, 163-71	16.6	11
229	Sleep and Alzheimer disease pathology--a bidirectional relationship. <i>Nature Reviews Neurology</i> , <b>2014</b> , 10, 115-9	15	457
228	Anti-ApoE antibody given after plaque onset decreases A $\beta$ accumulation and improves brain function in a mouse model of A $\beta$ amyloidosis. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7281-92	6.6	90
227	Blocking the apoE/A $\beta$ interaction ameliorates A $\beta$ -related pathology in APOE $\Delta$ and $\Delta$ targeted replacement Alzheimer model mice. <i>Acta Neuropathologica Communications</i> , <b>2014</b> , 2, 75	7.3	32
226	The binding of apolipoprotein E to oligomers and fibrils of amyloid- $\beta$ alters the kinetics of amyloid aggregation. <i>Biochemistry</i> , <b>2014</b> , 53, 6323-31	3.2	75
225	Altered microglial response to A $\beta$ plaques in APPS1-21 mice heterozygous for TREM2. <i>Molecular Neurodegeneration</i> , <b>2014</b> , 9, 20	19	203
224	Proteopathic tau seeding predicts tauopathy in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E4376-85	11.5	307

223	Phosphorylated tau-A $\beta$ 2 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. <i>Biological Psychiatry</i> , <b>2014</b> , 75, 723-31	7.9	58
222	Missense variant in TREML2 protects against Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 1510-19-2684	5.6	164
221	Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 271, 8-17	3.5	21
220	Neuronal activity regulates extracellular tau in vivo. <i>Journal of Experimental Medicine</i> , <b>2014</b> , 211, 387-93	16.6	319
219	Progress update: fluid and imaging biomarkers in Alzheimer's disease. <i>Biological Psychiatry</i> , <b>2014</b> , 75, 520-6	7.9	18
218	The sleep-wake cycle and Alzheimer's disease: what do we know?. <i>Neurodegenerative Disease Management</i> , <b>2014</b> , 4, 351-62	2.8	84
217	Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004758	6	84
216	Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. <i>Journal of Experimental Medicine</i> , <b>2014</b> , 211, 2487-96	16.6	138
215	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 226ra30	17.5	244
214	Lysosomal sorting of amyloid- $\beta$ by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 223ra20	17.5	100
213	Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice. <i>Stroke</i> , <b>2014</b> , 45, 3064-9	6.7	23
212	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1111-22	17.2	68
211	Functional connectivity and graph theory in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 757-68	5.6	230
210	In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. <i>Molecular Neurodegeneration</i> , <b>2013</b> , 8, 13	19	79
209	Antisense reduction of tau in adult mice protects against seizures. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 12887-97	6.6	198
208	Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. <i>Neuron</i> , <b>2013</b> , 80, 402-414	13.9	387
207	Biomarker modeling of Alzheimer's disease. <i>Neuron</i> , <b>2013</b> , 80, 1347-58	13.9	586
206	The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 17553-9	6.6	125

205	CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. <i>Neurology</i> , <b>2013</b> , 81, 2028-31	6.5	21
204	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. <i>Lancet Neurology</i> , <b>2013</b> , 12, 957-65	24.1	389
203	SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. <i>JAMA Neurology</i> , <b>2013</b> , 70, 201-7	17.2	77
202	Blocking the interaction between apolipoprotein E and A $\beta$ reduces intraneuronal accumulation of A $\beta$ and inhibits synaptic degeneration. <i>American Journal of Pathology</i> , <b>2013</b> , 182, 1750-68	5.8	55
201	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
200	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. <i>Neuron</i> , <b>2013</b> , 78, 256-68	13.9	255
199	Sleep quality and preclinical Alzheimer disease. <i>JAMA Neurology</i> , <b>2013</b> , 70, 587-93	17.2	414
198	The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE- $\epsilon$ 4 carriers. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003685	6	49
197	Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. <i>Genes and Development</i> , <b>2013</b> , 27, 565-78	12.6	73
196	Increased in vivo amyloid- $\beta$ 2 production, exchange, and loss in presenilin mutation carriers. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 189ra77	17.5	144
195	ApoE influences amyloid- $\beta$ clearance despite minimal apoE/A $\beta$ association in physiological conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E1807-16	11.5	336
194	Neuronal clearance of amyloid- $\beta$ by endocytic receptor LRP1. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 19276-836.6	164	
193	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. <i>Neurology</i> , <b>2013</b> , 80, 1784-91	6.5	175
192	Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. <i>PLoS ONE</i> , <b>2013</b> , 8, e64314	3.7	31
191	Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. <i>Brain Research</i> , <b>2012</b> , 1467, 120-32	3.7	23
190	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <i>Neurology</i> , <b>2012</b> , 79, 897-905	6.5	175
189	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 795-804	59.2	2272
188	Stealth attack: plaque-specific antibody allows for efficient A $\beta$ removal without side effects. <i>Neuron</i> , <b>2012</b> , 76, 859-61	13.9	1



187	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 4558-71	5.6	150
186	Toward a multifactorial model of Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 2262-71	5.6	42
185	Trans-cellular propagation of Tau aggregation by fibrillar species. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 19440-51	5.4	393
184	Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid $\beta$ peptide. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 15181-92	6.6	176
183	Multiple $\beta$ secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. <i>Molecular Neurodegeneration</i> , <b>2012</b> , 7, 16	19	13
182	Measurement of apolipoprotein E and amyloid $\beta$ clearance rates in the mouse brain using bolus stable isotope labeling. <i>Molecular Neurodegeneration</i> , <b>2012</b> , 7, 14	19	19
181	Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. <i>Nature</i> , <b>2012</b> , 485, 512-6	50.4	813
180	Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of A $\beta$ uptake and degradation by astrocytes. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 13959-71	5.4	124
179	Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2, a006312	5.4	497
178	Disruption of the sleep-wake cycle and diurnal fluctuation of $\beta$ amyloid in mice with Alzheimer's disease pathology. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 150ra122	17.5	339
177	Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 8890-9	6.6	385
176	Deciphering Alzheimer disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2, a011460	5.4	116
175	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- $\beta$ . <i>Brain</i> , <b>2012</b> , 135, 2155-68	11.2	195
174	Tau elevations in the brain extracellular space correlate with reduced amyloid- $\beta$ levels and predict adverse clinical outcomes after severe traumatic brain injury. <i>Brain</i> , <b>2012</b> , 135, 1268-80	11.2	122
173	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A $\beta$ clearance in a mouse model of $\beta$ amyloidosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 15502-7	11.5	120
172	Bidirectional relationship between functional connectivity and amyloid- $\beta$ deposition in mouse brain. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 4334-40	6.6	129
171	Alzheimer disease in 2020. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2,	5.4	82
170	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , <b>2012</b> , 2, 975-984		144

169	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A $\beta$ amyloidosis. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 2149-56	16.6	92
168	In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. <i>PLoS ONE</i> , <b>2012</b> , 7, e38013	3.7	34
167	Neuronal activity regulates the regional vulnerability to amyloid- $\beta$ deposition. <i>Nature Neuroscience</i> , <b>2011</b> , 14, 750-6	25.5	589
166	CSF biomarkers for Alzheimer's disease: current utility and potential future use. <i>Neurobiology of Aging</i> , <b>2011</b> , 32 Suppl 1, S4-9	5.6	76
165	The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 270-9	1.2	5630
164	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 386-395.e6	1.2	291
163	O1-05-01: APOE4 plays a role in A $\beta$ -mediated synapse loss in Alzheimer's disease <b>2011</b> , 7, S103-S104		
162	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease <b>2011</b> , 7, S287-S287		
161	Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e16032	3.7	124
160	Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e15918	3.7	57
159	Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. <i>NeuroReport</i> , <b>2011</b> , 22, 489-93	1.7	32
158	Apolipoprotein E in Alzheimer's disease and other neurological disorders. <i>Lancet Neurology</i> , <b>2011</b> , 10, 241-52	24.1	568
157	Alzheimer's disease: the challenge of the second century. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 77sr1	17.5	893
156	Diffusion characteristics associated with neuronal injury and glial activation following hypoxia-ischemia in the immature brain. <i>Magnetic Resonance in Medicine</i> , <b>2011</b> , 66, 839-45	4.4	30
155	Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. <i>Annals of Neurology</i> , <b>2011</b> , 70, 274-85	9.4	113
154	The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on A $\beta$ -induced membrane disruption. <i>ACS Chemical Neuroscience</i> , <b>2011</b> , 2, 588-599	5.7	24
153	Opposing synaptic regulation of amyloid- $\beta$ metabolism by NMDA receptors in vivo. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 11328-37	6.6	47
152	Reply to: Fractional synthesis and clearance rates for amyloid $\beta$ <i>Nature Medicine</i> , <b>2011</b> , 17, 1179-1180	50.5	3

151	Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid- $\beta$ amyloidosis. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 18007-12	6.6	138
150	Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1013-9		87
149	Human apoE isoforms differentially regulate brain amyloid- $\beta$ peptide clearance. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 89ra57	17.5	721
148	Comparison of analytical platforms for cerebrospinal fluid measures of $\beta$ amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1137-44		138
147	In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 13110-7	6.6	256
146	Dynamic analysis of amyloid $\beta$ protein in behaving mice reveals opposing changes in ISF versus parenchymal A $\beta$ during age-related plaque formation. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 15861-9	6.6	85
145	Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 19054-9	11.5	47
144	Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. <i>PLoS ONE</i> , <b>2011</b> , 6, e18850	3.7	168
143	APP-Based Transgenic Models: The PDAPP Model. <i>Neuromethods</i> , <b>2011</b> , 371-385	0.4	
142	SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001101	6	90
141	Cerebrospinal fluid biomarkers of Alzheimer's disease. <i>Biomarkers in Medicine</i> , <b>2010</b> , 4, 51-63	2.3	58
140	Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. <i>Biological Psychiatry</i> , <b>2010</b> , 67, 581-3	7.9	19
139	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 903-12	7.9	298
138	Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1188-96	5.6	55
137	Biomarkers in translational research of Alzheimer's disease. <i>Neuropharmacology</i> , <b>2010</b> , 59, 310-22	5.5	46
136	IC-PL-01: Diagnostic markers: Detection of preclinical pathology, prognostic capabilities, and dynamic metabolism of A $\beta$ and tau <b>2010</b> , 6, S1-S1		
135	Traumatic brain injury reduces soluble extracellular amyloid- $\beta$ in mice: a methodologically novel combined microdialysis-controlled cortical impact study. <i>Neurobiology of Disease</i> , <b>2010</b> , 40, 555-64	7.5	43
134	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. <i>Annals of Neurology</i> , <b>2010</b> , 67, 122-31	9.4	618

133	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. <i>Annals of Neurology</i> , <b>2010</b> , 68, 311-8	9.4	205
132	Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 21, 833-42	4.3	43
131	Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 4252-62	6.6	298
130	Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal brain injury. <i>ASN Neuro</i> , <b>2009</b> , 1,	5.3	17
129	Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. <i>Archives of Neurology</i> , <b>2009</b> , 66, 638-45		148
128	Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1557-62		165
127	Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1469-75		350
126	Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 10706-14	6.6	182
125	Biomarkers of Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 128-40	7.5	134
124	Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. <i>Annals of Neurology</i> , <b>2009</b> , 65, 176-83	9.4	272
123	A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. <i>Annals of Neurology</i> , <b>2009</b> , 66, 48-54	9.4	262
122	A surrogate marker for Abeta42 production in the CNS. <i>EMBO Molecular Medicine</i> , <b>2009</b> , 1, 195-7	12	
121	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2009</b> , 1, 371-80	12	278
120	Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. <i>Molecular Neurodegeneration</i> , <b>2009</b> , 4, 51	19	29
119	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. <i>Nature</i> , <b>2009</b> , 461, 916-22	50.4	474
118	The role of apolipoprotein E in Alzheimer's disease. <i>Neuron</i> , <b>2009</b> , 63, 287-303	13.9	1032
117	Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. <i>Neuron</i> , <b>2009</b> , 64, 632-44	13.9	185
116	Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1552-3		2

115	Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. <i>Science</i> , <b>2009</b> , 326, 1005-7	33.3	922
114	Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2009</b> , 8, 144-59	2.6	30
113	Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. <i>Nature</i> , <b>2008</b> , 451, 720-4	50.4	774
112	Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. <i>Neuron</i> , <b>2008</b> , 58, 42-51	13.9	455
111	ApoE promotes the proteolytic degradation of Abeta. <i>Neuron</i> , <b>2008</b> , 58, 681-93	13.9	680
110	Active and passive immunotherapy for neurodegenerative disorders. <i>Annual Review of Neuroscience</i> , <b>2008</b> , 31, 175-93	17	202
109	Amyloid-beta dynamics correlate with neurological status in the injured human brain. <i>Science</i> , <b>2008</b> , 321, 1221-4	33.3	253
108	Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 14156-64	6.6	122
107	apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 4002-13	15.9	509
106	Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 13542-50	6.6	109
105	Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 8050-4	11.5	74
104	Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 671-82	15.9	258
103	ANTI-AMYLOID- $\beta$ IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE <b>2008</b> , 295-318		1
102	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. <i>Annals of Neurology</i> , <b>2007</b> , 61, 446-53	9.4	67
101	Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. <i>Molecular Neurodegeneration</i> , <b>2007</b> , 2, 7	19	54
100	Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , <b>2007</b> , 1, 1373-84	3.1	47
99	Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2007</b> , 27, 909-18	7.3	495
98	Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 10673-8	11.5	162

97	Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. <i>Neurology</i> , <b>2007</b> , 68, 666-9	6.5	201
96	Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. <i>Developmental Neuroscience</i> , <b>2007</b> , 29, 363-72	2.2	117
95	Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. <i>Archives of Neurology</i> , <b>2007</b> , 64, 343-9		727
94	Role of A $\beta$ Transport and Clearance in the Pathogenesis and Treatment of Alzheimer's Disease <b>2007</b> , 179-198		5
93	Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. <i>Neurobiology of Disease</i> , <b>2006</b> , 22, 523-37	7.5	45
92	Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2006</b> , 24, 506-15	7.5	254
91	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A $\beta$ 42 in humans. <i>Annals of Neurology</i> , <b>2006</b> , 59, 512-9	9.4	1009
90	Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 14919-24	11.5	154
89	Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal A $\beta$ 42 accumulation in amyloid model mice. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 36180-6	5.4	103
88	Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. <i>Experimental Neurology</i> , <b>2006</b> , 197, 330-40	5.7	139
87	Amyloid-beta immunotherapies in mice and men. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, 118-23	2.5	14
86	Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. <i>Nature Medicine</i> , <b>2006</b> , 12, 856-61	50.5	441
85	Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. <i>Neurobiology of Disease</i> , <b>2005</b> , 19, 66-76	7.5	84
84	Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. <i>Neuron</i> , <b>2005</b> , 48, 913-22	13.9	882
83	Maternal dietary supplementation with pomegranate juice is neuroprotective in an animal model of neonatal hypoxic-ischemic brain injury. <i>Pediatric Research</i> , <b>2005</b> , 57, 858-64	3.2	115
82	Role of caspase-3 in ethanol-induced developmental neurodegeneration. <i>Neurobiology of Disease</i> , <b>2005</b> , 20, 608-14	7.5	107
81	Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. <i>Molecular and Cellular Proteomics</i> , <b>2005</b> , 4, 2000-9	7.6	96
80	Calcium-stimulated adenylyl cyclases modulate ethanol-induced neurodegeneration in the neonatal brain. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 2376-85	6.6	34

79	Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 6213-20	6.6	118
78	Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 629-36	6.6	278
77	Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 43236-42	5.4	243
76	The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 25754-9	5.4	104
75	Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 2803-10	6.6	227
74	Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 428-33	15.9	140
73	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 3285-90	15.9	459
72	Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 1075-80	11.5	120
71	ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 40987-93	5.4	304
70	In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. <i>Journal of Molecular Neuroscience</i> , <b>2004</b> , 23, 247-54	3.3	103
69	In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins. <i>Journal of Colloid and Interface Science</i> , <b>2004</b> , 278, 96-106	9.3	30
68	A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. <i>American Journal of Pathology</i> , <b>2004</b> , 165, 937-48	5.8	122
67	ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. <i>American Journal of Pathology</i> , <b>2004</b> , 165, 1413-22	5.8	50
66	Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. <i>Journal of Molecular Biology</i> , <b>2004</b> , 335, 997-1006	6.5	88
65	ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. <i>Neuron</i> , <b>2004</b> , 41, 193-202	13.9	355
64	Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 8043-51	5.4	94
63	Amyloid- $\beta$ -Binding Molecule. <i>Alzheimer Disease and Associated Disorders</i> , <b>2003</b> , 17, S66-S68	2.5	2
62	Potential role of endogenous and exogenous amyloid-beta binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , <b>2003</b> , 17, 151-3	2.5	4

61	Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 7889-96	6.6	130
60	In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8844-53	6.6	369
59	PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. <i>Journal of Comparative Neurology</i> , <b>2003</b> , 456, 375-83	3.4	57
58	Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. <i>Annals of Neurology</i> , <b>2003</b> , 54, 115-9	9.4	100
57	Use of YFP to study amyloid-beta associated neurite alterations in live brain slices. <i>Neurobiology of Aging</i> , <b>2003</b> , 24, 1071-7	5.6	21
56	Differential metabolism of ApoE isoforms in plasma and CSF. <i>Experimental Neurology</i> , <b>2003</b> , 183, 4-6	5.7	14
55	Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. <i>Neurobiology of Disease</i> , <b>2003</b> , 14, 10-8	7.5	134
54	Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , <b>2003</b> , 17 Suppl 2, S66-8	2.5	1
53	Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 10083-7	6.6	92
52	Expression of human apolipoprotein E downregulates amyloid precursor protein-induced ischemic susceptibility. <i>Stroke</i> , <b>2002</b> , 33, 1905-10	6.7	8
51	Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , <b>2002</b> , 54, 1603-13	18.5	52
50	Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. <i>Annals of Neurology</i> , <b>2002</b> , 52, 54-61	9.4	280
49	Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , <b>2002</b> , 81, 229-36	6	208
48	Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 30128-36	5.4	141
47	Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 10843-8	11.5	273
46	Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. <i>Journal of Biochemistry</i> , <b>2002</b> , 132, 743-9	3.1	38
45	Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. <i>Science</i> , <b>2002</b> , 295, 2264-7	33.3	495
44	Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2002</b> , 9, 305-18	7.5	217



43	Abeta conformational change is central to Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2002</b> , 23, 1085-8	5.6	10
42	Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. <i>Journal of Neurochemistry</i> , <b>2001</b> , 77, 1168-80	6	400
41	Role of nerve growth factor in experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 625-33	6.1	51
40	Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. <i>Journal of Molecular Neuroscience</i> , <b>2001</b> , 17, 147-55	3.3	107
39	Reply to [Inhibition of post-ischemic brain injury by clusterin overexpression] <i>Nature Medicine</i> , <b>2001</b> , 7, 978-979	50.5	1
38	Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. <i>Nature Medicine</i> , <b>2001</b> , 7, 338-43	50.5	182
37	Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. <i>Neurochemistry International</i> , <b>2001</b> , 39, 415-25	4.4	134
36	Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. <i>Journal of Alzheimer's Disease</i> , <b>2001</b> , 3, 23-30	4.3	74
35	BAX Contributes to Apoptotic-Like Death Following Neonatal Hypoxia-Ischemia: Evidence for Distinct Apoptosis Pathways. <i>Molecular Medicine</i> , <b>2001</b> , 7, 644-655	6.2	110
34	Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. <i>Microscopy Research and Technique</i> , <b>2000</b> , 50, 297-304	2.8	64
33	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. <i>Annals of Neurology</i> , <b>2000</b> , 47, 739-747	9.4	262
32	Differences in the A $\beta$ 40/A $\beta$ 42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. <i>Annals of Neurology</i> , <b>2000</b> , 48, 201-210	9.4	110
31	No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo. <i>European Journal of Neuroscience</i> , <b>2000</b> , 12, 2235-42	3.5	18
30	Lipoproteins in the central nervous system. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 903, 167-175	163	
29	Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. <i>Journal of Neuroscience</i> , <b>2000</b> , 20, 542-9	6.6	254
28	BDNF protects against spatial memory deficits following neonatal hypoxia-ischemia. <i>Experimental Neurology</i> , <b>2000</b> , 166, 99-114	5.7	151
27	BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. <i>Neurobiology of Disease</i> , <b>2000</b> , 7, 38-53	7.5	237
26	Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 106, 1489-99	15.9	996

25	BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. <i>Journal of Neuroscience</i> , <b>2000</b> , 20, 5775-81	6.6	436
24	Differences in the A $\beta$ 0/A $\beta$ 2 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype <b>2000</b> , 48, 201		3
23	Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 30001-7	5.4	152
22	Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1999</b> , 19, 331-40	7.3	199
21	In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>1999</b> , 58, 1020-6	3.1	119
20	Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 103, R15-R21	15.9	253
19	Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. <i>Trends in Cardiovascular Medicine</i> , <b>1998</b> , 8, 250-5	6.9	27
18	Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. <i>Experimental Neurology</i> , <b>1998</b> , 151, 314-25	5.7	102
17	Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. <i>Journal of Neuroscience</i> , <b>1998</b> , 18, 3261-72	6.6	196
16	Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. <i>Journal of Neuroscience</i> , <b>1998</b> , 18, 1009-10.6		224
15	A role for TrkA during maturation of striatal and basal forebrain cholinergic neurons in vivo. <i>Journal of Neuroscience</i> , <b>1997</b> , 17, 7644-54	6.6	120
14	Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic-ischemic brain injury. <i>Annals of Neurology</i> , <b>1997</b> , 41, 521-9	9.4	164
13	The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, modulates hippocampal neurite development. <i>Journal of Neurochemistry</i> , <b>1997</b> , 68, 587-95	6	76
12	Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. <i>Journal of Neurochemistry</i> , <b>1997</b> , 69, 1904-11	6	204
11	Neonatal mice lacking neuronal nitric oxide synthase are less vulnerable to hypoxic-ischemic injury. <i>Neurobiology of Disease</i> , <b>1996</b> , 3, 64-71	7.5	171
10	Expression of neuronal-NOS in developing basal forebrain cholinergic neurons: regulation by NGF. <i>Neurochemical Research</i> , <b>1996</b> , 21, 861-8	4.6	34
9	Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. <i>Annals of Neurology</i> , <b>1996</b> , 39, 114-22	9.4	130
8	The human trisomy 21 brain: Insights from mouse models of Down syndrome. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , <b>1996</b> , 2, 66-72		5

7	Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 30121-5	54	174
6	NOS induction by NGF in basal forebrain cholinergic neurones: evidence for regulation of brain NOS by a neurotrophin. <i>Neurobiology of Disease</i> , <b>1994</b> , 1, 51-60	7.5	55
5	p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. <i>Neuron</i> , <b>1992</b> , 9, 465-78	13.9	351
4	Functional insights from biophysical study of TREM2 interactions with ApoE and A $\beta$ -42		1
3	Polygenic Risk Score of Sporadic late Onset Alzheimer Disease Reveals a Shared Architecture with the Familial and Early Onset Forms		1
2	High affinity interactions and signal transduction between A $\beta$ oligomers and TREM2		2
1	Cholesterol and matrisome pathways dysregulated in human APOE $\epsilon$ 4 glia		11